Enlicitide, an oral cholesterol-lowering drug, is drawing interest from clinicians as an option for patients who would rather skip injections. Merck has also achieved a key step in its cholesterol drug pipeline, while a cholesterol medicine developed with McMaster University research has received approval in Canada.

Health outlets this week looked into how exercise affects LDL cholesterol levels, and TODAY.com warned people about following cholesterol advice found on social media. LDL cholesterol is often called the 'bad' type because high levels are linked to heart disease.